OTLK · Outlook Therapeutics, Inc.
$0.64
+0.02 (+2.86%)
At close · Aug 27
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We evaluated whether there are conditions or events considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern. We do not believe that the existing cash and cash equivalents, together with net proceeds of $51.1 million from the August 2026 Offering, as of June 30, 2026 are sufficient to fund the Company's operations through one year from the date of this Quarterly Report on Form 10-Q. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Market Cap
$157.07M
Shares
243.45M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.41M
FY2025
Net Income
-$62.42M
+17.2%
FY2025
Gross Margin
4.05%
FY2025
Operating Margin
-4744.25%
FY2025
Diluted EPS
-$1.79
+55.9%
FY2025
Operating Cash Flow
-$51.83M
+24.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $1.41M | — | — | — | — | — | $8.15M | $3.09M | $3.81M | $2.98M | $5.22M | |
| -$264.15K | -$283.13K | -$3.16M | -$1.56M | -$1.49M | -$936.13K | -$1.76M | — | — | — | — | — | |
| — | $1.36M | — | — | — | — | — | — | — | — | — | — | |
| — | $57.21K | — | — | — | — | — | — | — | — | — | — | |
| — | 4.05% | — | — | — | — | — | — | — | — | — | — | |
| $17.36M | $27.18M | $41.76M | $26.45M | $42.33M | $38.96M | $26.34M | $23.81M | $18.5M | $23.81M | $32.76M | $38.88M | |
| $38.65M | — | $29.94M | $26.67M | $20.74M | $12.77M | $9.97M | $9.37M | $14.23M | $15.88M | $21.56M | $12.91M | |
| $36M | $39.94M | $29.94M | — | — | — | — | — | — | — | — | — | |
| — | $117.05K | $113.86K | $44.19K | $204.69K | $262.14K | $219.42K | $3.36M | $3.05M | $2.69M | $2.39M | $1.82M | |
| — | — | — | — | — | $51.73M | $36.84M | $44.45M | $32.73M | $39.69M | $54.33M | $51.78M | |
| -$55.64M | -$67.06M | -$71.7M | -$53.13M | -$63.07M | -$51.73M | -$36.84M | -$36.3M | -$29.64M | -$35.88M | -$51.35M | -$46.56M | |
| — | -4744.25% | — | — | — | — | — | -445.6% | -960.12% | -941.36% | -1723.3% | -892.13% | |
| — | -$66.94M | -$71.59M | -$53.08M | -$62.87M | -$51.46M | -$36.62M | -$32.94M | -$26.59M | -$33.19M | -$48.95M | -$44.74M | |
| — | — | $3.16M | $2.53M | — | — | $1.76M | $3.47M | $3.89M | $5.63M | $1.85M | $2.3M | |
| — | $89.74K | $906.15K | $971.48K | — | — | — | — | — | — | — | — | |
| -$165.19K | -$141.01K | -$100.74K | -$11K | -$48.73K | -$46.34K | — | — | — | — | — | — | |
| — | -$63.98M | -$75.36M | -$58.98M | -$66.05M | -$53.16M | -$38.51M | -$37.93M | -$33.74M | -$38.35M | -$53.2M | -$48.86M | |
| — | -$1.55M | $2800 | $2800 | $2800 | $2000 | -$3.27M | -$3.41M | -$3.65M | $501.5K | $103K | -$190.11K | |
| -$61.12M | -$62.42M | -$75.37M | -$58.98M | -$66.05M | -$53.16M | -$35.24M | -$34.52M | -$30.09M | -$38.85M | -$53.3M | -$47.39M | |
| — | -4416.22% | — | — | — | — | — | -423.81% | -974.62% | -1019.26% | -1788.91% | -908.05% | |
| — | — | — | — | — | — | — | — | — | — | — | -$1.28M | |
| -$61.12M | -$62.42M | -$75.37M | -$58.98M | -$66.05M | -$53.16M | -$48.87M | -$36.04M | -$48.02M | -$40.03M | -$63.14M | -$53M | |
| USD/shares | -$1.04 | -$1.79 | -$4.06 | -$4.72 | -$6.20 | -$7.00 | -$13.40 | — | -$24.40 | -$33.40 | -$73.40 | — |
| USD/shares | -$1.04 | -$1.79 | -$4.06 | -$4.72 | -$6.20 | -$7.00 | -$13.40 | — | -$24.40 | -$36.00 | -$73.40 | — |
| shares | — | 34.8M | 18.55M | 12.51M | 10.6M | 7.63M | 3.63M | 909.59K | 1.97M | 1.2M | 860.65K | 487.68K |
| shares | — | 34.8M | 18.55M | 12.51M | 10.6M | 7.63M | 3.63M | 909.59K | 1.97M | 1.2M | 860.65K | 487.68K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.52×
EV/EBIT
—
Peer median 10.92×
P/E (TTM)
—
Peer median 9.52×
Peer medians compare against the 303 similar-size Biotechnology companies (of 534 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 |
|---|---|
| Development And Commercialization Of Ons5010 Or Lytenava | $1,413,535 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Development And Commercialization Of Ons5010 Or Lytenava | -$67,061,666 | -$71,703,235 |
Operating Margin by Segment (%)
| Component | FY2025 |
|---|---|
| Development And Commercialization Of Ons5010 Or Lytenava | -4744.3% |
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
59 filings
59 filers
Visit website
Investor relations